In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016).
Pneumonia and skin and skin structure infections (SSSIs) caused by S. aureus can lead to serious bloodstream infections (BSIs). This study reports on potent telavancin in vitro activity (MIC90, 0.06 μg/mL; 100% susceptible) against 674 US S. aureus causing pneumonia or SSSI with associated BSI in hospitalized patients during 2012-2016.